The prognostic significance of radiation dose and residual tumor in the treatment of barrel-shaped endophytic cervical carcinoma

被引:48
作者
Paley, PJ [1 ]
Goff, BA [1 ]
Minudri, R [1 ]
Greer, BE [1 ]
Tamimi, HK [1 ]
Koh, WJ [1 ]
机构
[1] Univ Washington, Sch Med, Seattle, WA 98195 USA
关键词
D O I
10.1006/gyno.1999.5691
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The aim of this study was to evaluate the impact of total radiation dose on residual tumor and the prognostic significance of persistent disease in women with bulky, barrel-shaped cervical carcinoma who received definitive radiation followed by adjuvant hysterectomy. Methods. The medical records of 57 patients with bulky endophytic cervical carcinoma treated at the University of Washington between 1976 and 1997 were reviewed. All patients received external beam pelvic radiotherapy supplemented by intracavitary brachytherapy, followed by extrafascial hysterectomy 6 to 8 weeks later. Results. The mean pretreatment tumor diameter was 5.9 cm, with a range of 4-9 cm. Total radiation dose to point A ranged from 5040 to 9700 cGy, and the mean for the group was 7966 cGy. Residual disease was present in 35 (61%) of the hysterectomy specimens. The frequency of cervical tumor sterilization correlated significantly with the mean radiation dose to point A (P = 0.016). Patients without histologic residual disease had a significantly improved outcome, with 95% of patients remaining clinically free of disease at last follow-up, versus 31% of those with residual disease (P < 0.001). As expected, the pelvic control rate was excellent (100%) in patients with complete tumor eradication compared to the group with residual tumor (44%). Those with no residual disease enjoyed a significantly improved survival compared to those with residual tumor (P < 0.001). Furthermore, a statistically significant higher survival was realized in patients harboring only microscopic residual compared to those with either macroscopically evident tumor residuum and/or positive surgical margins (P = 0.036). Conclusions. Higher radiation doses are associated with an improved likelihood of tumor eradication in the treatment of bulky, endophytic cervical cancer and complete tumor sterilization at adjuvant hysterectomy is predictive of significantly enhanced survival and pelvic control. The high rate of histologic tumor persistence in our series emphasizes the need for more efficacious therapies in patients with bulky endophytic cervical cancer and argues for escalation of radiation dose even when adjuvant hysterectomy is planned. (C) 2000 Academic Press.
引用
收藏
页码:373 / 379
页数:7
相关论文
共 26 条
[1]   RATIONALE FOR USING PATHOLOGICAL TUMOR DIMENSIONS AND NODAL STATUS TO SUBCLASSIFY SURGICALLY TREATED STAGE-IB CERVICAL-CANCER PATIENTS [J].
ALVAREZ, RD ;
POTTER, ME ;
SOONG, SJ ;
GAY, FL ;
HATCH, KD ;
PARTRIDGE, EE ;
SHINGLETON, HM .
GYNECOLOGIC ONCOLOGY, 1991, 43 (02) :108-112
[2]   ANALYSIS OF FACTORS CONTRIBUTING TO TREATMENT FAILURES IN STAGE-IB AND STAGE-II-A CARCINOMA OF THE CERVIX [J].
CHUNG, CK ;
NAHHAS, WA ;
STRYKER, JA ;
CURRY, SL ;
ABT, AB ;
MORTEL, R .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1980, 138 (05) :550-556
[3]   ANALYSIS OF CENTRAL RECURRENT DISEASE IN STAGES-1 AND STAGES-2 SQUAMOUS CELL CARCINOMAS OF CERVIX ON INTACT UTERUS [J].
DURRANCE, FY ;
FLETCHER, GH ;
RUTLEDGE, FN .
AMERICAN JOURNAL OF ROENTGENOLOGY RADIUM THERAPY AND NUCLEAR MEDICINE, 1969, 106 (04) :831-&
[4]   THE RELATIONSHIP BETWEEN BRACHYTHERAPY DOSE AND OUTCOME IN PATIENTS WITH BULKY ENDOCERVICAL TUMORS TREATED WITH RADIATION ALONE [J].
EIFEL, PJ ;
THOMS, WW ;
SMITH, TL ;
MORRIS, M ;
OSWALD, MJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (01) :113-118
[5]   THE INFLUENCE OF TUMOR SIZE AND MORPHOLOGY ON THE OUTCOME OF PATIENTS WITH FIGO STAGE IB SQUAMOUS-CELL CARCINOMA OF THE UTERINE CERVIX [J].
EIFEL, PJ ;
MORRIS, M ;
WHARTON, JT ;
OSWALD, MJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (01) :9-16
[6]  
GALLION HH, 1985, CANCER, V56, P262, DOI 10.1002/1097-0142(19850715)56:2<262::AID-CNCR2820560210>3.0.CO
[7]  
2-A
[8]  
HOMESLEY HD, 1980, SURG GYNECOL OBSTET, V150, P529
[9]  
HOSKINS W J, 1976, Gynecologic Oncology, V4, P278, DOI 10.1016/0090-8258(76)90033-0
[10]  
KEYS H, 1997, CANCER J SCI AM, V3, P117